Disease · MONDO_0016218

Guillain-Barre syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Guillain-Barre syndrome. Diseases, record MONDO_0016218. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016218

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Guillain-Barre syndrome; Open Targets
Open Targets ID: MONDO_0016218; Open Targets
Other names: GBS, Guillain Barré syndrome, Guillain-Barre syndrome (disorder), Guillain-Barre-Strohl syndrome, Guillain-Barré-Strohl syndrome, Infectious neuronitis (disorder), Post-infectious polyneuritis (disorder), Postinfectious polyneuritis, acute Infective Polyneuritis, acute inf. polyneuritis, acute infective polyneuritis (disorder), acute infective polyneuritis NOS (disorder), acute postinfectious polyneuropathy; Open Targets
Disease Ontology: DOID:12842; Disease Ontology
MeSH: D020275; MeSH
NCI Thesaurus: C116345; NCI Thesaurus
Orphanet: ORPHA:2103; Orphanet
Highest stage of its drugs: Approval, for 1 of its 7 drugs, from EMA Human Drugs; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Approval	EMA Human Drugs	11	7	0	Drugs and targets
ECULIZUMAB	CHEMBL1201828	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ANX-005	CHEMBL4650442		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CROVALIMAB	CHEMBL4594316	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
DALFAMPRIDINE	CHEMBL284348	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
IMLIFIDASE	CHEMBL4297981	Enzyme	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
C5	Complement C5	2	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
FCGRT	IgG receptor FcRn large subunit p51	1	IgG receptor FcRn large subunit p51 antagonist	Phase 2/3	https://conductscience.org/library/genes/2217	Drugs and targets
KCNA1	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3736	Drugs and targets
KCNA10	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3744	Drugs and targets
KCNA2	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3737	Drugs and targets
KCNA3	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3738	Drugs and targets
KCNA4	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3739	Drugs and targets
KCNA5	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3741	Drugs and targets
KCNA6	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3742	Drugs and targets
KCNA7	Voltage-gated potassium channel	1	Voltage-gated potassium channel blocker	Phase 2	https://conductscience.org/library/genes/3743	Drugs and targets

1 to 10 of 42

See all 42 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04752566	A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome	Phase 3	57	2024-02-09	Guillain-Barre Syndrome	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03943589	A Study of Imlifidase in Patients With Guillain-Barré Syndrome	Phase 2	30	2025-04-09	Guillain-Barré Syndrome (GBS)	IMLIFIDASE	Its record names the disease	ClinicalTrials.gov
NCT04701164	Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome	Phase 3	242		Guillain-Barre Syndrome	ANX-005	Its record names the disease	ClinicalTrials.gov
NCT02493725	JET-GBS - Japanese Eculizumab Trial for GBS	Phase 2	34		Gullain Barre Syndrome	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02029378	Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study	Phase 2	30		Gullian Barre Syndrome	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06885762	Efgartigimod for the Treatment of Guillain-Barré Syndrome	Phase 2/3	20		Guillain-Barre Syndrome (GBS)	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT04035135	A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)	Phase 1	14		Guillain-Barré Syndrome	ANX-005	Its record names the disease	ClinicalTrials.gov
NCT05494619	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)	Phase 3	0		Guillain-Barré Syndrome	CROVALIMAB	Its record names the disease	ClinicalTrials.gov
NCT05701189	Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome	Phase 2	0		Guillain-Barre Syndrome	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Eculizumab vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	34 of 37	19 of 20	57	NCT04752566	Trial comparisons
Eculizumab vs Placebo: Number of Participants With A Hughes Functional Grade Score Improvement of >=3	16 of 37	10 of 20	57	NCT04752566	Trial comparisons
Eculizumab vs Placebo: Number of Participants Who Required Mechanical Ventilator Support	8 of 37	1 of 20	57	NCT04752566	Trial comparisons
Eculizumab vs Placebo: Number of Participants With Positive Antidrug Antibodies	0 of 37	0 of 20	57	NCT04752566	Trial comparisons
Eculizumab vs Placebo: deaths from any cause	1 of 37	0 of 20	57	NCT04752566	Trial comparisons
Eculizumab vs Placebo: serious adverse events	4 of 37	1 of 20	57	NCT04752566	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38987228	DERIVED	1	PubMed
29685815	DERIVED	1	PubMed
27821382	DERIVED	1	PubMed
27801990	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016218

GET https://conductscience.org/api/diseases/v1/MONDO_0016218/targets?page=2

API reference For AI assistants